TYENNE
(Tyenne)Preclinical
TYENNE is one of 22 biologic programs targeting B-cell acute lymphoblastic leukemia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in B-Cell Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Fludara
SanofiPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Blincyto
AmgenPhase 2
Tisagenlecleucel
NovartisPhase 2
CTL019
NovartisPhase 3
Erbitux
IImclone
Phase 1
YK012
EExcyte Biopharma Ltd
Phase 2
Inaticabtagene Autoleucel
JJuventas Cell Therapy Ltd.
Phase 2
CAR-T Cell
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Mar 5, 2024
TYENNE
BLA BLA761275
Mar 14, 2025
TYENNE
BLA BLA761449
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tyenne. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- FFresenius Kabi Taiwan Ltd.